• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

潜伏膜蛋白2B的沉默降低了伯基特淋巴瘤Akata细胞中EB病毒裂解激活的易感性。

Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells.

作者信息

Rechsteiner Markus P, Berger Christoph, Weber Matthias, Sigrist Jürg A, Nadal David, Bernasconi Michele

机构信息

Experimental Infectious Diseases and Cancer Research, University Children's Hospital of Zurich, Zurich, Switzerland.

出版信息

J Gen Virol. 2007 May;88(Pt 5):1454-1459. doi: 10.1099/vir.0.82790-0.

DOI:10.1099/vir.0.82790-0
PMID:17412973
Abstract

Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) blocks B-cell receptor (BCR) signalling after BCR cross-linking to inhibit activation of lytic EBV, and ectopically expressed LMP2B negatively regulates LMP2A. Here, it is demonstrated that silencing of LMP2B in EBV-harbouring Burkitt's lymphoma Akata cells results in reduced expression of EBV immediate-early lytic BZLF1 gene mRNA and late lytic gp350/220 protein upon BCR cross-linking. Similarly, reduction of lytic EBV activation was observed in Akata cells overexpressing LMP2A. In contrast, silencing of LMP2A expression resulted in higher lytic EBV mRNA and protein expression in BCR cross-linked Akata cells. These observations indicate a role for LMP2B distinct from that of LMP2A in regulation of lytic EBV activation in the host cell and support the hypothesis that LMP2B exhibits a negative-regulatory effect on the ability of LMP2A to maintain EBV latency by preventing the switch to lytic replication.

摘要

爱泼斯坦-巴尔病毒(EBV)潜伏膜蛋白2A(LMP2A)在B细胞受体(BCR)交联后阻断BCR信号传导,以抑制EBV裂解激活,而异位表达的LMP2B对LMP2A起负调节作用。在此,研究表明,在携带EBV的伯基特淋巴瘤Akata细胞中沉默LMP2B,会导致BCR交联后EBV立即早期裂解BZLF1基因mRNA和晚期裂解gp350/220蛋白的表达降低。同样,在过表达LMP2A的Akata细胞中也观察到裂解性EBV激活减少。相反,在BCR交联的Akata细胞中沉默LMP2A表达会导致更高的裂解性EBV mRNA和蛋白表达。这些观察结果表明,LMP2B在宿主细胞中调节裂解性EBV激活方面具有与LMP2A不同的作用,并支持以下假设:LMP2B通过防止向裂解复制的转变,对LMP2A维持EBV潜伏的能力表现出负调节作用。

相似文献

1
Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells.潜伏膜蛋白2B的沉默降低了伯基特淋巴瘤Akata细胞中EB病毒裂解激活的易感性。
J Gen Virol. 2007 May;88(Pt 5):1454-1459. doi: 10.1099/vir.0.82790-0.
2
Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection.潜伏膜蛋白2B调节对裂解性爱泼斯坦-巴尔病毒感染诱导的易感性。
J Virol. 2008 Feb;82(4):1739-47. doi: 10.1128/JVI.01723-07. Epub 2007 Dec 5.
3
Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells.泽布替尼可重新激活沉默的E-钙黏蛋白,但与5-氮杂胞苷不同的是,它不会在伯基特淋巴瘤Akata细胞中诱导爱泼斯坦-巴尔病毒从潜伏感染转变为裂解感染。
Mol Cancer. 2007 Jan 10;6:3. doi: 10.1186/1476-4598-6-3.
4
IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.IRF4 促进伯基特淋巴瘤细胞中 EBV 的激活。
J Gen Virol. 2019 May;100(5):851-862. doi: 10.1099/jgv.0.001249. Epub 2019 Mar 25.
5
Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.干扰素-γ诱导蛋白 16(IFI16)是维持 Epstein-Barr 病毒潜伏所必需的。
Virol J. 2017 Nov 13;14(1):221. doi: 10.1186/s12985-017-0891-5.
6
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.B淋巴细胞中EBNA1阳性潜伏状态下EB病毒基因激活的三条途径。
J Virol. 1992 Jan;66(1):122-31. doi: 10.1128/JVI.66.1.122-131.1992.
7
Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.抑制 LMP2A 靶基因 EGR-1 可保护霍奇金淋巴瘤细胞免受 EBV 裂解周期的影响。
J Pathol. 2013 Aug;230(4):399-409. doi: 10.1002/path.4198.
8
Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity.爱泼斯坦-巴尔病毒潜伏膜蛋白2B(LMP2B)调节LMP2A的活性。
J Virol. 2007 Jan;81(1):84-94. doi: 10.1128/JVI.01302-06. Epub 2006 Oct 11.
9
Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation.爱泼斯坦-巴尔病毒编码的潜伏膜蛋白2A在病毒诱导的永生化和病毒激活中的作用。
J Gen Virol. 2001 Jun;82(Pt 6):1451-1456. doi: 10.1099/0022-1317-82-6-1451.
10
The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.将爱泼斯坦-巴尔病毒潜伏膜蛋白2A(LMP2A)与LMP2B区分开来的唯一结构域,在体外淋巴细胞感染和生长转化过程中并非必需;因此,LMP2A并非不可或缺。
J Virol. 1992 Nov;66(11):6461-9. doi: 10.1128/JVI.66.11.6461-6469.1992.

引用本文的文献

1
Integrated Pan-Cancer Map of EBV-Associated Neoplasms Reveals Functional Host-Virus Interactions.泛癌种 EBV 相关肿瘤综合图谱揭示了功能宿主-病毒相互作用。
Cancer Res. 2019 Dec 1;79(23):6010-6023. doi: 10.1158/0008-5472.CAN-19-0615. Epub 2019 Sep 3.
2
TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification.TLR9 触发 Burkitt 淋巴瘤细胞系通过组蛋白修饰抑制 EBV BZLF1 转录。
Oncogene. 2010 Aug 12;29(32):4588-98. doi: 10.1038/onc.2010.203. Epub 2010 May 31.
3
The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation.
爱泼斯坦-巴尔病毒(EBV)编码的潜伏膜蛋白LMP2A和LMP2B通过靶向干扰素受体进行降解来限制干扰素的作用。
Oncogene. 2009 Nov 5;28(44):3903-14. doi: 10.1038/onc.2009.249. Epub 2009 Aug 31.
4
EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway.EBV LMP2A通过ERK/MAPK途径的组成性激活提供替代前B细胞受体信号。
J Gen Virol. 2008 Jul;89(Pt 7):1563-1568. doi: 10.1099/vir.0.2008/001461-0.
5
Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection.潜伏膜蛋白2B调节对裂解性爱泼斯坦-巴尔病毒感染诱导的易感性。
J Virol. 2008 Feb;82(4):1739-47. doi: 10.1128/JVI.01723-07. Epub 2007 Dec 5.
6
An auto-regulatory loop for EBV LMP2A involves activation of Notch.EBV LMP2A的一个自动调节环路涉及Notch的激活。
Virology. 2008 Feb 20;371(2):257-66. doi: 10.1016/j.virol.2007.10.009. Epub 2007 Nov 5.